Funder: Cancer Research Institute
Due Dates (Anticipated): December 2025 (Initial Protocol Concept) | April 2026 (Invited Full Proposal)
Funding Amounts: Up to $1 million per clinical trial; milestone-based payments; no indirect costs allowed.
Summary: Supports innovative phase I/II or phase II clinical trials in cancer immunotherapy with a focus on mechanistic insights and biomarker discovery.
Key Information: Open to academic clinician-scientists worldwide; no for-profit institutions; strong data sharing and reporting requirements.